SWAV Stock Overview
A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Shockwave Medical, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$334.75 |
52 Week High | US$334.90 |
52 Week Low | US$157.00 |
Beta | 0.88 |
11 Month Change | 1.49% |
3 Month Change | 27.08% |
1 Year Change | 15.77% |
33 Year Change | 97.43% |
5 Year Change | 432.11% |
Change since IPO | 997.54% |
Recent News & Updates
Recent updates
Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors
Apr 06Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?
Mar 24Shockwave Medical: Opening Arteries, Delivering Returns
Feb 28Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 18There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital
Feb 06Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)
Jan 24Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio
Jan 09Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?
Dec 27Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?
Dec 13What Is Shockwave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?
Nov 17Is Shockwave Medical, Inc. (NASDAQ:SWAV) Trading At A 50% Discount?
Oct 19Shockwave Medical (NASDAQ:SWAV) Is Very Good At Capital Allocation
Oct 06Shockwave Medical (NASDAQ:SWAV) Has A Rock Solid Balance Sheet
Sep 20Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?
Sep 07When Should You Buy Shockwave Medical, Inc. (NASDAQ:SWAV)?
Jul 10We Think Shockwave Medical (NASDAQ:SWAV) Might Have The DNA Of A Multi-Bagger
Jun 26We Think Shockwave Medical (NASDAQ:SWAV) Can Manage Its Debt With Ease
Jun 13Is Now The Time To Put Shockwave Medical (NASDAQ:SWAV) On Your Watchlist?
May 29Shareholder Returns
SWAV | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0.2% | -0.7% | -2.1% |
1Y | 15.8% | 22.5% | 29.7% |
Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned 3.8% over the past year.
Return vs Market: SWAV underperformed the US Market which returned 25.2% over the past year.
Price Volatility
SWAV volatility | |
---|---|
SWAV Average Weekly Movement | 3.6% |
Medical Equipment Industry Average Movement | 8.0% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SWAV has not had significant price volatility in the past 3 months.
Volatility Over Time: SWAV's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,468 | Doug Godshall | shockwavemedical.com |
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina.
Shockwave Medical, Inc. Fundamentals Summary
SWAV fundamental statistics | |
---|---|
Market cap | US$12.57b |
Earnings (TTM) | US$163.50m |
Revenue (TTM) | US$787.97m |
76.9x
P/E Ratio15.9x
P/S RatioIs SWAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SWAV income statement (TTM) | |
---|---|
Revenue | US$787.97m |
Cost of Revenue | US$102.53m |
Gross Profit | US$685.44m |
Other Expenses | US$521.94m |
Earnings | US$163.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 05, 2024
Earnings per share (EPS) | 4.35 |
Gross Margin | 86.99% |
Net Profit Margin | 20.75% |
Debt/Equity Ratio | 97.5% |
How did SWAV perform over the long term?
See historical performance and comparison